Eli Lilly TPM system design interview guide 2026

TL;DR

Eli Lilly’s TPM system design interviews test for pharma-scale tradeoffs, not just distributed systems knowledge. Candidates fail when they default to FAANG patterns instead of addressing regulatory, compliance, and data integrity constraints. The bar is high because a single misstep can derail a $1B+ drug pipeline.

Who This Is For

This is for mid-to-senior TPMs (L5-L7 equivalent) with 5-10 years of experience in regulated industries or enterprise SaaS, targeting Eli Lilly’s TPM roles in digital health, clinical trials, or manufacturing systems. You’ve shipped systems at scale but need to recalibrate for a world where FDA 21 CFR Part 11 and HIPAA are non-negotiable constraints, not afterthoughts. If your last interview was at a hypergrowth startup, your playbook is incomplete.

How is Eli Lilly’s TPM system design interview different from FAANG?

It’s not a harder version of the same interview—it’s a different game. In a Q2 2025 debrief for a clinical data pipeline role, the hiring manager killed a candidate after 15 minutes because their design for a patient data lake treated PHI as “just another data field.” The problem wasn’t technical depth; it was the absence of compliance as a first-class requirement.

FAANG system design interviews reward optimization for scale, cost, and latency. Eli Lilly rewards optimization for auditability, traceability, and risk mitigation. The not X, but Y: not “how do we handle 10M QPS,” but “how do we prove to a regulator that no record was altered after submission.” Your framework must include compliance as a core pillar, not a bolt-on.

Eli Lilly’s TPM interviews also probe deeper into cross-functional alignment. In a 2024 panel for a manufacturing execution system (MES) role, the candidate’s downfall was assuming the design constraints were purely technical. The HC pushed back: “You haven’t addressed how the shop floor operators will interact with this.” The signal? Eli Lilly TPMs are expected to bridge the gap between engineering and GxP (Good Practice) requirements, not just architect systems.

What are the most common Eli Lilly TPM system design questions?

You’ll face 2-3 system design rounds, each 45-60 minutes, with a focus on pharma-specific systems. Expect questions like: design a clinical trial data ingestion pipeline, a drug batch tracking system, or a global patient identity resolution service. The twist: every question includes implicit constraints like 21 CFR Part 11, GCP (Good Clinical Practice), or ICH (International Council for Harmonisation) guidelines.

In a 2025 interview for a digital therapeutics TPM, the candidate was asked to design a system for real-time adverse event reporting from wearable devices. The hiring manager’s feedback: “They nailed the real-time processing but missed the requirement for immutable audit logs.” The not X, but Y: not “how do we process streams fast,” but “how do we ensure every event is tamper-proof and attributable.”

Another frequent prompt: design a system to manage global drug inventory with expiration tracking. The trap? Assuming it’s a standard inventory system. The reality: you must account for temperature-controlled logistics, chain of custody, and recall capabilities. In a debrief, one HC noted, “The candidate treated it like Amazon inventory. We need FDA-grade traceability.”

How do you structure your answer for Eli Lilly’s compliance-first culture?

Lead with the constraint, not the solution. In a 2024 interview for a regulatory submission system, the top candidate started with: “Given 21 CFR Part 11, we need to ensure electronic records are trustworthy, secure, and auditable. Here’s how that shapes the design.” The hiring manager later called it “the only answer that sounded like it came from someone who’s worked in pharma.”

Your structure should explicitly call out:

Compliance requirements (e.g., 21 CFR Part 11, HIPAA, GxP)
Non-functional requirements (auditability, traceability, data integrity)
Scale and performance constraints (but only after the above)
Tradeoffs (e.g., “We sacrifice some query speed for immutable logging”)

The not X, but Y: not “here’s my scalable design,” but “here’s my compliant design that also scales.” Eli Lilly interviewers are trained to listen for this framing. If you bury compliance, you’re signaling you don’t understand the domain.

In a 2025 debrief for a failed candidate, the HC said, “They gave a perfect answer for a fintech company. But we’re not fintech.” The judgment signal? If your answer could work for Stripe, it’s probably wrong for Eli Lilly.

What tradeoffs do Eli Lilly TPMs prioritize that FAANG TPMs don’t?

Eli Lilly TPMs optimize for risk, not velocity. In a 2024 hiring committee for a clinical data TPM, the debate centered on a candidate who proposed a microservices architecture for a trial data system. The pushback: “What’s the rollback plan if a single service fails during an FDA audit?” The candidate’s answer—“We’d deploy a hotfix”—was met with silence. The unspoken rule: in pharma, the cost of a failure isn’t downtime; it’s a warning letter or a trial hold.

The tradeoffs you’ll be judged on:

Data integrity over write performance (e.g., immutable logs vs. fast updates)
Auditability over cost (e.g., full history retention vs. storage optimization)
Validation over speed (e.g., extensive testing vs. rapid iteration)

The not X, but Y: not “we’ll trade consistency for availability,” but “we’ll trade some availability for guaranteed consistency.” In Eli Lilly’s world, eventual consistency is a non-starter for critical systems.

Another tradeoff: vendor lock-in vs. compliance. In a 2025 interview, a candidate proposed using a cloud-native database for a patient data system. The follow-up: “How do you ensure the vendor meets HIPAA and 21 CFR Part 11?” The candidate’s vague answer about “trusting the vendor’s compliance certifications” doomed them. The lesson: Eli Lilly expects you to treat vendor compliance as a design requirement, not an assumption.

How do you handle the “tell me about a time” behavioral questions?

Eli Lilly’s behavioral questions are a stress test for compliance mindset. Expect prompts like: “Tell me about a time you had to balance business needs with regulatory requirements” or “Describe a situation where you had to push back on a stakeholder due to compliance risks.”

In a 2024 interview, a candidate described a project where they shipped a feature under tight deadlines, only to later discover it violated internal SOPs. The interviewer’s response: “At Eli Lilly, that’s a firing offense.” The not X, but Y: not “here’s how I delivered under pressure,” but “here’s how I ensured compliance under pressure.”

Your STAR stories must:

Explicitly name the regulation or standard (e.g., “We were subject to 21 CFR Part 11”)
Show proactive risk mitigation (e.g., “I flagged the gap in our audit trail early”)
Demonstrate cross-functional alignment (e.g., “I worked with Legal and QA to revise the requirements”)

A 2025 HC noted, “The best candidates don’t just describe compliance—they describe how they enforced it.” If your story doesn’t include a moment where you said “no” to a stakeholder for compliance reasons, it’s not strong enough.

What salary and leveling should you expect for Eli Lilly TPM roles?

Eli Lilly’s TPM roles are typically levelled as Senior TPM (L5 equivalent) or Principal TPM (L6-L7). For 2026, expect:

Senior TPM: $150K–$180K base, $20K–$30K bonus, $20K–$40K RSUs
Principal TPM: $180K–$220K base, $30K–$40K bonus, $40K–$60K RSUs

The not X, but Y: not “negotiate for the highest number,” but “negotiate for the package that aligns with your risk tolerance.” Eli Lilly’s RSUs vest over 3 years, and the stock has been volatile. In a 2025 offer negotiation, a candidate walked away because the RSU grant was too heavily weighted toward performance-based vesting. The HC later admitted, “We lost a strong candidate because we misaligned on risk.”

Preparation Checklist

Map Eli Lilly’s compliance requirements (21 CFR Part 11, GxP, HIPAA) to system design pillars—treat them as non-negotiable constraints, not features.
Study pharma-specific systems: clinical trial data pipelines, MES, adverse event reporting, drug inventory tracking, and patient identity resolution.
Prepare 3-4 STAR stories where compliance was the primary challenge, not a secondary concern.
Practice designing for auditability: immutable logs, tamper-proof timestamps, and chain of custody are mandatory.
Work through a structured preparation system (the PM Interview Playbook covers pharma-specific system design frameworks with real debrief examples from regulated industries).
Mock interview with a focus on tradeoffs: be ready to justify why you’d sacrifice performance for compliance.
Research Eli Lilly’s recent FDA warning letters or 483s to understand their pain points (e.g., 2023 warning letter for data integrity issues).

Mistakes to Avoid

BAD: Treating compliance as an afterthought.

GOOD: Leading with compliance and structuring your design around it. Example: “Given 21 CFR Part 11, our database must support immutable audit logs. Here’s how that affects our schema.”

BAD: Assuming FAANG patterns apply.

GOOD: Tailoring your design to pharma constraints. Example: “Unlike a social media feed, our clinical data pipeline cannot use eventual consistency because regulators require absolute data integrity.”

BAD: Ignoring cross-functional stakeholders.

GOOD: Explicitly addressing how non-engineers (e.g., QA, Legal, shop floor operators) interact with the system. Example: “For the MES, we’ll include operator training as part of the design to ensure GxP compliance.”

FAQ

What’s the biggest red flag in an Eli Lilly TPM system design answer?

The biggest red flag is a design that prioritizes scalability or cost over compliance. If your answer doesn’t explicitly address how you’ll meet 21 CFR Part 11 or HIPAA, you’re signaling you don’t understand the domain. In a 2025 debrief, a HC said, “If they don’t mention audit logs in the first 5 minutes, they’re out.”

How many system design rounds are there in Eli Lilly’s TPM interview process?

There are typically 2-3 system design rounds, each 45-60 minutes, often paired with 1-2 behavioral rounds. The process also includes a cross-functional panel (e.g., Engineering, QA, Compliance) to stress-test your ability to align with non-technical stakeholders.

Do you need pharma experience to pass Eli Lilly’s TPM interview?

No, but you need to demonstrate a compliance-first mindset. In a 2024 hire, the candidate came from fintech but framed every answer around auditability and risk mitigation. The HC noted, “They didn’t have pharma experience, but they thought like a pharma TPM.” The not X, but Y: not “do you have pharma experience,” but “can you prove you understand pharma constraints?”

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.